These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 34126710)
21. Amyloidosis: a case series and review of the literature. Senecal JB; Abou-Akl R; Allevato P; Mazzetti I; Hamm C; Parikh R; Woldie I J Med Case Rep; 2023 Apr; 17(1):184. PubMed ID: 37081462 [TBL] [Abstract][Full Text] [Related]
22. Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina. Posadas-Martinez ML; Aguirre MA; Brulc E; Saez MS; Sorroche P; Machnicki G; Fernandez M; Nucifora EM PLoS One; 2022; 17(10):e0274578. PubMed ID: 36301970 [TBL] [Abstract][Full Text] [Related]
23. Treatment of immunoglobulin light chain (primary or AL) amyloidosis. Gertz MA; Buadi FK; Hayman SR Oncology (Williston Park); 2011 Jun; 25(7):620-6. PubMed ID: 21888261 [TBL] [Abstract][Full Text] [Related]
24. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Rubin J; Maurer MS Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086 [TBL] [Abstract][Full Text] [Related]
25. Amyloidosis of the Heart and Kidney. Adrogue HE Methodist Debakey Cardiovasc J; 2022; 18(4):27-33. PubMed ID: 36132587 [TBL] [Abstract][Full Text] [Related]
26. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Gertz MA Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248 [TBL] [Abstract][Full Text] [Related]
27. COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury. Crees ZD; Stockerl-Goldstein K Am J Med; 2022 Apr; 135 Suppl 1():S49-S52. PubMed ID: 35081378 [TBL] [Abstract][Full Text] [Related]
28. Future Developments in Light Chain Amyloidosis Management. Rodriguez M; Lenihan D; Merlini G Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388 [TBL] [Abstract][Full Text] [Related]
29. Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. Martins CO; Lezcano C; Yi SS; Landau HJ; Chapman JR; Dogan A Haematologica; 2018 Dec; 103(12):e610-e612. PubMed ID: 30262557 [No Abstract] [Full Text] [Related]
30. Ptosis and macroglossia in a woman with systemic light-chain amyloidosis. Hsiao PJ; Chang YC; Tsao YH; Wu KL; Kao YH; Chan JS; Wang CH; Lin YY; Chuu CP; Lin YS Clin Chim Acta; 2019 Jul; 494():112-115. PubMed ID: 30905590 [TBL] [Abstract][Full Text] [Related]
37. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review]. Hu Y; Zhu P Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159 [TBL] [Abstract][Full Text] [Related]
38. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis. Ravichandran S; Law S; Mahmood S; Wisniowski B; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD Leukemia; 2022 Apr; 36(4):1180-1184. PubMed ID: 34987193 [No Abstract] [Full Text] [Related]
39. Recent advances in the management of AL Amyloidosis. Kastritis E; Dimopoulos MA Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974 [TBL] [Abstract][Full Text] [Related]